Celgene is reportedly in talks to buy a $5.5 billion cancer drugmaker (JUNO, CELG)

pulse

January 16, 2018 11:51 PM

If the deal materializes, it'd be the second in 2018 for the biotech giant, which has been under pressure from investors.

Celgene is in talks to acquire Juno Therapeutics,
If the deal materializes, it'd be the second in 2018 for the biotech giant, which has been under pressure from investors.
Juno is known for its experimental treatments that harness the body's immune system to treat cancer.

Biotech giant Celgene is in talks to buy cancer drugmaker Juno Therapeutics, The Wall Street Journal reports.

Celgene has been under pressure from investors to make some changes after a rocky 2017. Already in 2018, the company acquired$7 billion deal, a move that didn't entirely excite the biotech community.

Juno declined to comment on the report.

Juno is developing a CAR T-cell therapy

Juno was up 40% Tuesday evening on the report.

pulse